Analyzing Enliven Therapeutics (NASDAQ:ELVN) and Vivos Therapeutics (NASDAQ:VVOS)

Enliven Therapeutics (NASDAQ:ELVN) and Vivos Therapeutics (NASDAQ:VVOS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Volatility & Risk

Enliven Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the S&P 500.

Profitability

This table compares Enliven Therapeutics and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Enliven Therapeutics and Vivos Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1	0	4	1	2.83
Vivos Therapeutics	1	1	2	0	2.25

Enliven Therapeutics presently has a consensus price target of $58.40, indicating a potential upside of 47.59%. Vivos Therapeutics has a consensus price target of $2.75, indicating a potential upside of 292.86%. Given Vivos Therapeutics’ higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than Enliven Therapeutics.

Valuation and Earnings

This table compares Enliven Therapeutics and Vivos Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69 million	($1.67)	-23.69
Vivos Therapeutics	$19.57 million	0.50	-$21.17 million	($2.14)	-0.33

Vivos Therapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Enliven Therapeutics beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.